← Back to Search

Immunosuppressant

Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid

Phase 2
Waitlist Available
Research Sponsored by Washington University School of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights
No Placebo-Only Group
Approved for 5 Other Conditions
All Individual Drugs Already Approved

Summary

This trial is testing whether the drug baricitinib can improve symptoms in people with ocular mucous membrane pemphigoid, a rare autoimmune disorder that can lead to vision loss.

Eligible Conditions
  • Mucous Membrane Pemphigoid
  • Cicatrizing Conjunctivitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Treatment Response

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: BaricitinibExperimental Treatment1 Intervention
4mg daily
Group II: AntiproliferativeActive Control3 Interventions
methotrexate, azathioprine, or mycophenolate

Find a Location

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
2,000 Previous Clinical Trials
2,344,260 Total Patients Enrolled
Eli Lilly and CompanyIndustry Sponsor
2,680 Previous Clinical Trials
3,466,382 Total Patients Enrolled

Media Library

Azathioprine (Immunosuppressant) Clinical Trial Eligibility Overview. Trial Name: NCT05263505 — Phase 2
Mucous Membrane Pemphigoid Research Study Groups: Baricitinib, Antiproliferative
Mucous Membrane Pemphigoid Clinical Trial 2023: Azathioprine Highlights & Side Effects. Trial Name: NCT05263505 — Phase 2
Azathioprine (Immunosuppressant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05263505 — Phase 2
~1 spots leftby Dec 2025